TILRAY INC – TLRY NASDAQ
Bank America Target $21.50 BUY NOW
TL Private Wealth Fund Buys Tilray
4 Analysts Say Strong Buy
Marijuana is coming alive once again . A new marijuana bill will hit the Senate floor shortly . One step closer to Federal legalization opening ease of transportation between states ,and banking regulations being relaxed.
The chips are down and the last cards dealt . WATCH FOR A BREAKOUT ABOVE $17.5O with an intermediate stop at $22 and a run towards $33 and higher.
Climb aboard this train . SERIOUS TRADERS SHOULD PLACE THESE SHARES ON THEIR WATCH LIST FOR A BREAKOUT
TLRY Stock: 3 Great Reasons to Buy Tilray
There has been a lot of noise in the market in 2021. The rise and fall of so-called social media “meme” stocks like Canadian cannabis producer Tilray (NASDAQ:TLRY) stock may be the noisiest phenomenon of the first half of the year.
Meme stock mania has focused mainly on stocks that have extremely high short interest. The problem is that these heavily shorted stocks are not chosen at random. Short sellers mostly target stocks with businesses in secular decline. Companies on the brink of bankruptcy, stocks that have become overly hyped and businesses that are burning cash hand-over-fist are popular targets for short sellers.
In that respect, most of the popular meme stocks of 2021 are actually terrible long-term investments.
But there are a handful of relatively high-quality stocks that are mixed in among the lemons. A closer look at TLRY stock reveals a company that has a lot of things going for it. In fact, Tilray could make an excellent long-term speculative investment. Here are three reasons to buy TLRY stock.
TLRY Stock Has Aphria Synergies
When you take a look at TLRY stock in 2021, you must start with the Aphria merger. The deal officially closed on May 3, making Tilray the world’s largest cannabis company by revenue.
The combination with Aphria creates unrivaled scale for Tilray. It also provides plenty of cost-cutting opportunities in the Canadian market, according to Morningstar analyst Kristoffer Inton. He says:
“We view the target CAD 100 million [$81.1 million] of cost synergies as achievable as they represent just 9% of combined costs and overhead expenses and we see significant low-hanging fruit.”
He says Tilray management historically demonstrated a responsible approach to spending. In an industry in which profitability and cash burn are still major issues, cost cutting is critical. Tilray has selectively invested in growing its business. But it has not overextended its balance sheet and has navigated a challenging Canadian cannabis market.
Tilray Has Domestic and International Presence
Canada is the main market for legal cannabis sales in the world today. However, most long-term cannabis investors believe Canada is just the first step in a global legalization process.
Today’s Canadian cannabis companies are working to balance two goals. First, they are establishing an early footprint in the Canadian market. Second, they are attempting to position themselves in key international markets.
Cantor Fitzgerald analyst Pablo Zuanic said the Aphria merger gives Tilray great positioning on both fronts.
“Except in recent months (deal-related distraction?), Aphria was one of the best performers in Canada [recreational cannabis] achieving a #1 position (speaking in organic terms, and did so while achieving positive cannabis EBITDA), and Tilray ran ahead of peers in the export cannabis markets,” Zuanic says. “We do not see another [legal producer] that can make these combined claims.”
Zuanic says Canadian scale, an international sales platform and a credible management team are three keys to success for cannabis stocks. Zuanic has an “overweight” rating and $22 price target for TLRY stock.
Tilray Is Ready to Pounce on the U.S. Market
The golden goose for cannabis investors is U.S. federal legalization. At this point it’s unclear how far away full U.S. legalization is. But it certainly seems like the ball is moving in that direction.
Bank of America analyst Heather Balsky says Tilray’s recent proposal to increase its share count is a hint at Tilray’s approach to the U.S.
“The Board notes in the proxy that the additional authorized shares are to help the company pursue M&A and financing opportunities. We surmise that the company is specifically focused on preparing itself for eventual US cannabis legalization,” Balsky says.
She says the post-merger Tilray is in a good spot to improve its liquidity position. In addition, she says Tilray has a path to generate consistently positive earnings before interest, taxes, depreciation and amortization and expand the TLRY stock earnings multiple over time.
Bank of America has a “buy” rating and $21.50 price target for TLRY stock.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate. Future events and results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statement
Pure Harvest Reports Exceptional Revenue Growth for 2020
GREENWOOD VILLAGE, CO, April 22, 2021 (GLOBE NEWSWIRE) — via NewMediaWire ‒ Pure Harvest Corporate Group, Inc. (OTCQB: PHCG), a publicly traded holding company focused on emerging and high-growth industries, is pleased to announce it has reported extraordinary growth in revenues for 2020 as compared to 2019 in its most recent annual report, 10K filing.
PHCG’s reported gross revenues for 2020 increased more than 1,800% from 2019. This growth is largely the result of sales generated by the Company’s licensed marijuana operations located in Dumont, Colorado. The Company’s 2020 Q4 sales grew by more than 8,400% compared to Q4 2019 and increased 29% as compared to Q3 2020.
“This growth in revenue is extremely exciting but not at all unexpected,” said Matthew Gregarek, CEO of Pure Harvest Corporate Group. “We have spent considerable time and energy to get to this point and I’m very proud of the entire PHCG team for making all of this possible.”
“As we continue to expand our marijuana operations in Colorado, we will be able to focus on additional opportunities and potential revenue streams to maintain this exceptional growth moving forward,” said Gregarek. “Despite all the challenges brought about by Covid 19, 2020 was an incredible year for Pure Harvest. We believe that our Q1 numbers will continue this amazing trend and we are confident that 2021 will be a big year for our Company.”
About Pure Harvest Corporate Group
Pure Harvest Corporate Group, Inc. (OTCQB: PHCG) is a publicly traded holding company focused on emerging and high-growth industries. The PHCG team is committed to formulating, manufacturing, and distributing high-quality cannabis and hemp derived cannabinoid consumer products in markets where it is legal to do so. The Company has developed numerous retail brands and product lines that are currently available for purchase in select markets. Pure Harvest intends to grow its marijuana, hemp derived cannabinoids, and research and development operations and expand globally as the laws regarding cannabis are reviewed and rewritten to repeal their prohibition.
Additionally, the Company may from time to time disclose public material events via its website at http://www.PureHarvestGroup.com or its social media accounts at the following locations:
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate. Future events and results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. Writer has been paid $2500